|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,141.00 GBX | -0.42% |
|
+2.93% | +17.35% |
| 12/02 | Intron Health Downgrades GSK to Sell Rating, Lifts PT | MT |
| 12/02 | Sanofi ousts CEO Hudson after stalled turnaround at vaccine giant | RE |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | GBX 19.7 | -8.38% | 20 | ||||||
| $1,201.63 | +18.36% | 27 | ||||||
| $231.25 | -3.99% | 24 | ||||||
| $245.33 | +11.07% | 27 | ||||||
| CHF 353.3 | -0.98% | 20 | ||||||
| CHF 148.31 | -7.06% | 21 | ||||||
| GBX 211.1 | +4.41% | 21 | ||||||
| $123.54 | +3.54% | 26 | ||||||
| DKK 382.55 | +24.73% | 22 | ||||||
| $343.96 | -6.17% | 27 | ||||||
| $151.84 | -2.54% | 25 | ||||||
| $28.63 | +3.24% | 24 | ||||||
| $59.91 | -0.03% | 23 | ||||||
| €99.14 | +20.08% | 23 | ||||||
| $514.32 | +11.51% | 25 | ||||||
| JP¥9,280 | +2.86% | 15 | ||||||
| JP¥5,289.73 | -5.22% | 15 | ||||||
| CN¥82.91 | +40.77% | 17 | ||||||
| €43.23 | -6.29% | 20 | ||||||
| GBX 4.224 | +3.97% | 16 | ||||||
| Average | 940.73 | +5.19% | 22 | ||||||
| Weighted average by Cap. | 652.26 | +5.86% | 24 |
- Stock Market
- Equities
- GSK Stock
- Sector GSK plc
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition